Biotech developing CD31 agonists to restore immune balance for autoimmune disease
| Date | Round | Amount |
|---|---|---|
| Sep 2022 | Series A Tridek-One, a Paris autoimmune biotech, raised $16.1M led by Pureos Bioventures. | $16.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.